NCT07393672 Effects of Hemp-Derived Cannabinoids on Menopause Symptoms
| NCT ID | NCT07393672 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Washington State University |
| Condition | Menopause |
| Study Type | INTERVENTIONAL |
| Enrollment | 104 participants |
| Start Date | 2026-02-11 |
| Primary Completion | 2026-11-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 104 participants in total. It began in 2026-02-11 with a primary completion date of 2026-11-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of the study is to examine the impact of hemp-derived minor cannabinoids on symptoms of menopause/perimenopause.
Eligibility Criteria
Inclusion Criteria: * designated female at birth * 40-60 years of age * able to give informed consent (no intellectual disability) * stable pharmacotherapeutic regimen, no change in the past 3 months * abstinent from regular cannabis use (\<1x/month) for past year, and willing to abstain from use for 3 months * abstinent for supplements, don't add any supplements (no changes in past 3 months) * own a smartphone * have access to Zoom on a secure, stable internet connection * perimenopausal or menopausal Exclusion Criteria: * currently taking anti-depressant, anti-anxiety, and/or antipsychotic medication * severe depression, neurovegetative symptoms, or current suicidality * psychosis or family history of psychosis * pregnant or breastfeeding * chemotherapy * hypotension * drug testing for work or other reasons * illicit drug use in past 3 months (cannabis not illicit) * heavy alcohol use (4 drinks more than 4x/week) * international/air travel planned for more than one week in the next 3 months * cocounut allergy
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07393672 clinical trial?
This trial is open to female participants only, aged 40 Years or older, up to 60 Years, studying Menopause. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07393672 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07393672 currently recruiting?
Yes, NCT07393672 is actively recruiting participants. Contact the research team at carrie.cuttler@wsu.edu for enrollment information.
Where is the NCT07393672 trial being conducted?
This trial is being conducted at Pullman, United States.
Who is sponsoring the NCT07393672 clinical trial?
NCT07393672 is sponsored by Washington State University. The trial plans to enroll 104 participants.